CMS has advised Abris CEE Mid-Market III LP on the acquisition, made through its subsidiary NEPT Holdings, of a stake in ITP S.A., which operates in the aesthetic medicine industry. The sellers of the stake, ITP's founders, were represented by Wierzbowski Eversheds Sutherland.
Abris Capital Partners has been managing private equity funds since 2006. According to Abris, “the acquisition of shares in ITP S.A. is the fifth investment from the EUR 500 million fund secured in autumn 2017 from international investors.”
According to Wierzbowski Eversheds Sutherland, "ITP S.A. was founded in Poland in 2006, by Gabriel Drigo, Dominik Sliwowski, and others, as a biomedical distributor company. It has since created its own R&D and its own products and devices—Neauvia, Zaffiro, and ITP Cosmeceuticals—and become one of the leading soft tissues fillers and cosmeceuticals manufacturers in Poland, with its own brands, as well as a distributor of wellness equipment and medical devices across Europe and globally."
The CMS team advising Abris CEE Mid-Market III LP was led by Warsaw-based Partners Rafal Zwierz and Graham Conlon and Senior Associate Olga Czyzycka, assisted by lawyers from CMS’s Milan, Geneva, and Berlin offices.
The Wierzbowski Eversheds Sutherland team advising ITP's founders included Partners Michal Karwacki and Ewa Szlachetka, Counsels Renata Patoka and Anna Derdak, Senior Associate Natalia Burchardt, and Associates Marek Tolcz and Zofia Piekarczyk.